New inhaled therapy targets Hard-to-Treat cystic fibrosis mutation
Disease control
Recruiting now
This study tests an experimental drug called SPL84 in adults with cystic fibrosis who have a specific genetic mutation (3849+10kb C->T). The drug is inhaled weekly for 9 to 12 weeks. Researchers want to see if it is safe and if it can improve lung function. Some participants will…
Phase: PHASE2 • Sponsor: SpliSense Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC